Incyte Corporation (INCY) Earnings Call Transcripts
Incyte Corporation's Latest Earnings Call - September 16, 2026
Incyte Corporation's earnings call on September 16, 2026, highlighted a significant transformation in its pipeline, with management indicating a potential revenue growth of 15% to 20% CAGR from 2030 to 2035. The company reported annualized sales of approximately $2 billion from its core business excluding JAKAFI, with a goal to reach $3 billion to $4 billion by 2030. Management maintained a positive outlook on the conversion of JAKAFI sales post-LOE, projecting formulary coverage for XR to reach 70%-80% by year-end, which could preserve around $0.75 billion in sales during the transition period.
Reported metrics
| Metric | Value |
|---|---|
| Core Business Annualized Sales | $2B (positive) |
| Projected CAGR | 15%-20% (positive) |
| JAKAFI Conversion Target | 10%-30% (positive) |
| Formulary Coverage for XR | 70%-80% (positive) |
| Pivotal Trial Initiation for 989 | Early 2027 (positive) |
| Acquisition Impact | Highly accretive (positive) |
Guidance from management
Management maintained a positive outlook for the future, projecting significant growth in core business sales and pipeline advancements, with specific timelines for pivotal trials and regulatory discussions.
What management said
No, I think it's a need to have. And Pablo can walk through the aspects of the program. But we expect at this point that at least within the first 6 to 9 months of the ET launch, will have an on-body subcu twice a month. I think it's especially relevant in ET. And there are several work streams in place, and we'll have more information on the third quarter call about our discussions with FDA. But that program, I thin...
So you'll see ORR. As you know, cetuximab single agent is single digits. So I think you'll see data that very clearly beat that. And you'll see a PFS as well for what it's worth, but it's a mature PFS. I think both give me -- give us conviction that we can beat the control arm. I won't talk about the details on the control arm until we have a discussion with FDA, but we're confident in the design that we are presenti...
What analysts pressed on
Analysts expressed concerns regarding the competitive landscape for JAKAFI and the potential impact of upcoming data from competitors like RINVOQ. There were also questions about the efficacy and safety profiles of new therapies in development.
Main topics on the call
- Pipeline Transformation — Management emphasized that the pipeline now includes proof-of-concept data for multiple therapies, including the CAAR antibody for MF and ET, and a G12D inhibitor for pancreatic cancer. Bill Meury stated, "the pipeline t...
- JAKAFI Sales Transition — The company is targeting a 10% to 30% conversion rate for JAKAFI sales post-LOE, with a midpoint of 20%. Meury noted, "If we're successful there, we preserve almost $0.75 billion in sales as we go through the transition....
- Next-Gen Antibody Development — Incyte is advancing its Calera antibody 989, with pivotal trials initiated for second-line ET and plans for frontline MF trials. Pablo Cagnoni mentioned, "Our intention is in the early part of '27 to initiate a frontline...
- Collaboration with Halozyme — The collaboration for an ENHANZE-enabled subcutaneous formulation of 989 is seen as a critical differentiator for commercial success. Meury stated, "I think it's especially relevant in ET," indicating its importance in t...
Read the full Incyte Corporation transcript (September 16, 2026) → Summary generated from the call transcript; every figure above is stated by management on the record.
About Incyte Corporation
Incyte Corporation (INCY) is a publicly listed company in the Biotechnology industry, within the Health Care sector. It trades on NasdaqGS and is based in US. EarningsCalls.dev maintains a free, full-text archive of its earnings call transcripts — 119 calls on record spanning January 2, 2020 to September 16, 2026. Every transcript is split into speaker-by-speaker segments with headline metrics, free to read or available through our REST API.
Earnings Call History
EarningsCalls.dev has 119 Incyte Corporation earnings call transcripts on record, spanning January 2, 2020 to September 16, 2026. Based on this history, Incyte Corporation reports quarterly. The most recent call on file is dated September 16, 2026. The full list is below — each row opens the complete, free-to-read transcript.
- Ticker
- INCY
- Exchange
- NasdaqGS
- Country
- US
- Sector
- Health Care
- Industry
- Biotechnology
- Calls on record
- 119
- First call
- January 2, 2020
- Most recent
- September 16, 2026
- Reporting cadence
- quarterly